CordenPharma is expanding sterile injectable manufacturing at its Caponago, Italy, site through a multi-year €80 million investment and additional aseptic fill-and-finish lines. The program includes the €13 million acquisition of an 11,000-square-meter commercial building and 26,000 square meters of adjacent land, completed on 28 July 2026, increasing the site footprint by more than 50%. Existing-site upgrades include two isolator lines, expanded packaging and doubled analytical capacity, with completion targeted for mid-2027 and 2028. The combined expansion is projected to support up to 500 million injectable units annually across formats and complex modalities, including peptides, LNPs, biologics and oligonucleotides.